Cytokinetics (CYTK) said Monday it has dosed the first participants in a phase 1 clinical study of CK-4015089 as a potential treatment for a specific type of muscular dystrophy and other impaired muscle conditions.
The randomized, double-blind, placebo-controlled study consists of single-dose and multiple-dose ascending cohorts of 10 participants each, said the company
The drug, also called CK-089, increased muscle force and function in animal testing, the company said.
Shares of the company were up 2% in recent Monday premarket activity.
Price: 57.00, Change: +1.16, Percent Change: +2.08
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。